The PK/PD model-derived individual drug potency on GDF-15 production on day 1 was associated with the drug thrombocytopenia potency, raising the possibility to use GDF-15 induction as a prospective marker in the identification of patients at a higher risk of developing delayed thrombocytopenia (Supplementary Fig. S1). This evidence concerns the gene GDF15 and Thrombocytopenia.